48 /100
MEDIUM RISK
Score updated Jul 14, 2026

PHIO — Phio Pharmaceuticals Corp. Dilution Risk Tracker

Track PHIO dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track PHIO — Get alerts when the score changes →

As of July 14, 2026, Phio Pharmaceuticals Corp. (PHIO) has a DilutionWatch DilutionScore of 48/100, rated MEDIUM dilution risk. Phio Pharmaceuticals Corp. has a market capitalization of $12.90M, 11.62M shares outstanding, 25 institutional holders tracked. Key dilution vectors include approximately 30 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
80
💰 Cash Runway
10
📊 Float Risk
10
⚠️ Warrant Exposure
40
🔄Convertible Debt

🌦️ Dilution Forecast

Watch
Minor dilution signals detected
15%
🔄 Reverse Split 30%
• 50-day avg $1.19 approaching $1 threshold
🔔 Track PHIO — Get forecast alerts →

💹 Market Data

Market Cap$12.90M
Shares Outstanding11.62M
Float11.55M
Cash$25.03M
DebtN/A
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 108.2% shares (2026Q1 vs prior)
25 institutional holders · 760.6K shares
#1 VANGUARD CAPITAL MANAGEMENT LLC 159.7K shares
#2 GEODE CAPITAL MANAGEMENT, LLC 147.3K shares
#3 JANE STREET GROUP, LLC 119.2K shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest218.7K
Days to Cover1.0
% of Float1.9%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Mar 31, 2026
xbrl XBRL CONVERTIBLE Dec 31, 2021
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for PHIO Shareholders

Phio Pharmaceuticals Corp. (PHIO) has a DilutionScore of 48/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 14, 2026.

DilutionWatch's EDGAR monitoring for PHIO shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for PHIO in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for PHIO alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track PHIO Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking PHIO — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for PHIO
📊 PHIO FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 PHIO Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.